The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes that's true
... and I hope Interferon beta-1a with IV injection is even more powerful.
Thanks Mathias,
The active pharmaceutical ingredient in Traumakine® is recombinant human IFN beta-1a.
Unfortunately, Professor Hung seems to be backing IFN Beta-1b.
I do not think they are the same but could well be my misunderstanding
It was good news from India but could not paste link. Just search with google:
"Top expert recommends triple antiviral therapy in COVID-19 treatment"
https://www.indiatvnews.com/news/world/top-expert-recommends-triple-antiviral-therapy-in-covid-19-treatment-exclusive-interview-ivan-hung-619586
Good sign for antivirals + interferon
I'm sure something this obvious wouldn't have escaped Marrku's attention.
He's already had the 'worst day if his life ' when the Phase 3 results came out - I can't believe he would put Traumakine forward in such high profile trials and risk a repeat if he thought this was an issue.
Thats what it reads to me more chance of dying without taking TK
Pot -
- TK, no corticosteroids 10,6% (7/66)
- TK with corticosteroids 39,7% (31/78)
- Placebo, no corticosteroids 14,8% (8/54)
- Placebo with corticosteroids 27,6 % (27/98)
If you take out the corticosteroids altogether its 10.6% vs 14.8% mortality. Unless my maths is wrong there is 40% greater chance of dying with just a placebo vs taking Traumakine. I would suggest that certainly helps with survival.
Please can someone correct me if I'm wrong!!
Research and comments does not worry me at all. But yes, this is pure finnish attitude to take "something" and start whining. Does not matter relevant or not, real or syrreal...
Hopefully the Fins continue researching by reading the follow up RNS's up to current date regarding the complications of corticosteroids in this treatment , and in use in general for patients suffering with ARDS and lung trauma .
If a clinician involved in REMAP or Solidarity , dosing patients , was not aware of the corticosteroid issue , they would be majorly at fault . It has been published widely , not at least by the WHO themselves , who strongly advise against use of corticosteroids in these cases .
As one swallow does not make a summer , One RNS does not make a whole story .
There is quite interesting discussion going on in one Finnish magazine´s (Kauppalehti) forum.
Could be one explanation, why the SP keeps resiliently so low (short term) and why there have been no press release about a partner for TK (yet at least).
It all comes down to the Faron´s press release from 22th of October 2018.
https://www.faron.com/index.php/news-events/news-and-press-releases?rnsid=1201489&cid=2223
First a couple of quotations:
”Concomitant corticosteroid treatment had a significant impact on mortality in the Traumakine treatment group. Mortality was 10.6% (7/66) for those receiving Traumakine and not on corticosteroids, versus 39.7% (31/78) for those receiving Traumakine and on concomitant corticosteroids. This outcome is highly statistically significant (p<0.0001) and was a similar mortality to the treatment group in the phase I/II study”
”Of note, we also observed that the use of corticosteroids in the placebo group was associated with an increased mortality of 27.6% compared to no use of corticosteroids of 14.8% (p= 0.075). In the group receiving corticosteroids there was a significantly higher APACHE II (acute physiology and chronic health evaluation) score (23.4 versus 20.4, p=0.0007) and SOFA (sequential organ failure assessment) score (10.4 vs 9.5, p=0.0428) but this difference does not, we believe, explain the scale of mortality difference associated with corticosteroid use versus non-use.”
Mortality extremely plain and short:
- TK, no corticosteroids 10,6% (7/66)
- TK with corticosteroids 39,7% (31/78)
- Placebo, no corticosteroids 14,8% (8/54)
- Placebo with corticosteroids 27,6 % (27/98)
Interesting pondering from the Finnish forum:
- It may be that there is no statisticly significant case on TK working here.
- The point is that corticosteroids kill.
- When no corticosteroids given, TK (10,6%) and placebo (14,8%) have not that remarkable difference. Especially when the results in placebo group are not statistically as significant. We don´t know yet how the end result would be if the groups were bigger and more evenly divided in numbers.
- If you were given corticosteroids, you probably would have wanted to be in the placebo group. You would have survived more likely than with TK.
So far we have been told, that TK is saving lives with huge margin. It indeed looks like that when the comparison group is using corticosteroids. But what happens when the comparison group is placebo only? That´s the truly interesting comparison to be made.
Oh, but I believe there is no such comparison in either of the 2 ongoing mega-studies=).
If no cytokine storms or other problems caused by IFN in (late stage Covid-19) patients arise, we just might be good in the short run too. We´ll see soon enough.
BR
Pot